510(k) · Cleared
ClearedFFRct
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
HeartFlow, Inc. · PJA Coronary Vascular Physiologic Simulation Software
Cleared on Jan 13, 2016 as substantially equivalent to DEN130045 (Heartflow, 2014) after a 113-day review. Its family tree reaches back 1 generation to 2014. 9 later devices descend from it.
- Decided
- Jan 13, 2016
- Review
- 113 days
- Class
- Class II
- Product code
- PJA
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to DEN130045 (2014). 9 later devices descend from it, 1 citing it directly.
- Root · 1 generation backDEN130045 Heartflow FfrctHeartflow · 2014
- This deviceK152733 FFRctHeartFlow, Inc. · 2016
- Descendant · cites it directly · 8 of its ownK161772 FFRctHeartFlow, Inc. · 2016
- Descendant · 2 generations on · 4 of its ownK182035 FFRctHeartFlow, Inc. · 2018
- Descendant · 3 generations on · 3 of its ownK190925 HeartFlow FFRct AnalysisHeartFlow, Inc. · 2019
- Descendant · 4 generations on · 2 of its ownK203329 HeartFlow AnalysisHeartFlow, Inc. · 2021
- Descendant · 5 generations on · 1 of its ownK213857 HeartFlow AnalysisHeartFlow, Inc. · 2022
Showing 5 of 9 descendants. See all descendants
Descendants cleared per year
Most influential descendants
Showing 5 of 9 · See all- K161772FFRctHeartFlow, Inc. · 2016 · cites it directly8descendants
- K182035FFRctHeartFlow, Inc. · 2018 · 2 generations on4descendants
- K190925HeartFlow FFRct AnalysisHeartFlow, Inc. · 2019 · 3 generations on3descendants
- K203329HeartFlow AnalysisHeartFlow, Inc. · 2021 · 4 generations on2descendants
- K213857HeartFlow AnalysisHeartFlow, Inc. · 2022 · 5 generations on1descendant
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | DEN130045 | Heartflow Ffrct | Heartflow | 2014 | — |
| 0 (this device) | K152733 | FFRct | HeartFlow, Inc. | 2016 | — |
| +1 | K161772 | FFRct | HeartFlow, Inc. | 2016 | — |
| +2 | K182035 | FFRct | HeartFlow, Inc. | 2018 | — |
| +3 | K190925 | HeartFlow FFRct Analysis | HeartFlow, Inc. | 2019 | — |
| +4 | K203329 | HeartFlow Analysis | HeartFlow, Inc. | 2021 | — |
| +5 | K213857 | HeartFlow Analysis | HeartFlow, Inc. | 2022 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2016 | 1 | 0 |
| 2018 | 2 | 0 |
| 2019 | 2 | 0 |
| 2021 | 1 | 0 |
| 2022 | 2 | 0 |
| 2025 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in PJA? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new PJA device
- #1 K250902 HeartFlow Analysisscore 13.0 · 12 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | DEN130045 | Heartflow FfrctSummary page 4…Device Product Code: PJA Product Class: Class II (21 CFR 870.1415) 5.3 Predicates HeartFlow FFRCT v1.4 (DEN130045) is the identified predicate for the HeartFlow FFRCT v2.0 product. This is discussed further in VOL_002 SEC 013 Substanti… | 2014 |
What descends from it? (9)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K161772 | FFRct | 2016 | 8 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
How does its category compare?
All PJA devicesPJA Coronary Vascular Physiologic Simulation Software: FDA decisions, review times, recalls and adverse event reports over 20 years. 2016, this device’s year, is highlighted.
FDA decisions per year · PJA
1in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · PJA
Too few PJA 510(k)s in any year since 2007 to give a median.
Recalls per year · PJA
No recall names PJA since 2007.
Adverse event reports per year · PJA
16in 2025
MAUDE reports naming product code PJA, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 1 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 2 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 4 |
| 2018 | 1 | — | 0 | 12 |
| 2019 | 1 | — | 0 | 65 |
| 2020 | 0 | — | 0 | 9 |
| 2021 | 1 | — | 0 | 2 |
| 2022 | 2 | — | 0 | 1 |
| 2023 | 0 | — | 0 | 8 |
| 2024 | 0 | — | 0 | 14 |
| 2025 | 1 | — | 0 | 16 |
| 2026 | 1 | — | 0 | — |
What is it indicated for?
HeartFlow FFRCT is a post-processing software for the clinical quantitative and qualitative analysis of previously acquired Computed Tomography DICOM data for clinically stable symptomatic patients with coronary artery disease. It provides FFRCT, a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images. FFRCT analysis is intended to…
Read the full statement (123 words)
HeartFlow FFRCT is a post-processing software for the clinical quantitative and qualitative analysis of previously acquired Computed Tomography DICOM data for clinically stable symptomatic patients with coronary artery disease. It provides FFRCT, a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images. FFRCT analysis is intended to support the functional evaluation of coronary artery disease.
The results of this analysis are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of HeartFlow FFRCT are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K152733 · printed Nov 6, 2026
Cite this page
510(k) Report. “K152733: FFRct.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K152733
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026